GABA Therapeutics, Inc
GABA Therapeutics is a midstage biotechnology company focused on developing novel therapies for psychiatric and neurological disorders. They are working on a deuterated version of etifoxine, called GRX-917, which aims to provide faster, lower-dose, and more stable treatment options for anxiety and related conditions. Their approach leverages deuteration technology to improve existing drugs, potentially increasing success rates and reducing side effects. The company has secured funding, is conducting clinical trials in Australia, and plans to move towards IPO within the next two years.
Industries
Nr. of Employees
small (1-50)
GABA Therapeutics, Inc
Products
Clinical‑stage deuterated anxiolytic candidate
A deuterated analog of an established anxiolytic designed to improve metabolic stability and pharmacokinetics while preserving a mechanism that increases endogenous neurosteroids and modulates inhibitory neurotransmission.
Clinical‑stage deuterated anxiolytic candidate
A deuterated analog of an established anxiolytic designed to improve metabolic stability and pharmacokinetics while preserving a mechanism that increases endogenous neurosteroids and modulates inhibitory neurotransmission.
Services
Collaborative drug development partnerships
Form co‑development alliances and strategic partnerships to advance clinical‑stage CNS compounds through early clinical milestones and to provide funding and development expertise.
Collaborative drug development partnerships
Form co‑development alliances and strategic partnerships to advance clinical‑stage CNS compounds through early clinical milestones and to provide funding and development expertise.
Expertise Areas
- Clinical trial management
- Neurosteroid pharmacology
- Deuteration medicinal chemistry
- qEEG biomarker development
Key Technologies
- Deuterium substitution (deuteration) chemistry
- Quantitative EEG (qEEG)
- TSPO modulation assays
- Neurosteroid quantification assays